Clinical Research

Researchers use multi-modality imaging to learn more about MINOCA
The combination of OCT and MRI can help provide an improved sense of clarity when managing MINOCA patients, according to new data presented at ACC.26 in New Orleans.
Evolocumab reduces risk of major cardiac events in diabetic patients
Late-breaking data out of ACC.26 suggest a more aggressive treatment approach for these patients could be beneficial.
Heart Rhythm 2026 to feature late-breaking EP data, hands-on training and more
Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.
Late-breaking PCI data challenge the 'time is muscle' paradigm
Gregg Stone, MD, spoke to Cardiovascular Business about the lessons he and his colleagues learned from the STEMI DTU trial.
Early SAVR in asymptomatic heart patients linked to long-term benefits
New 10-year data explored the impact of performing SAVR on asymptomatic patients with severe aortic stenosis.

Harmony Reynolds, MD, FACC, director of the cardiovascular clinical research center at NYU Langone Health, presented a study at the American College of Cardiology (ACC) 2026 meeting using coronary optical coherence tomography (OCT) and cardiac magnetic resonance imaging (MRI) to determine sex differences in underlying causes of myocardial infarction with no obstructive coronary arteries (MINOCA).

Researchers use multi-modality imaging to learn more about MINOCA

The combination of OCT and MRI can help provide an improved sense of clarity when managing MINOCA patients, according to new data presented at ACC.26 in New Orleans.

Nicholas Marston, MD, MPH assistant professor of medicine, and a cardiologist at Brigham and Women's Hospital, presented the late-breaking VESALIUS-CV data on the use of evolocumab for the reduction of major cardiovascular events in patients who do not have significant atherosclerosis. #ACC26

Evolocumab reduces risk of major cardiac events in diabetic patients

Late-breaking data out of ACC.26 suggest a more aggressive treatment approach for these patients could be beneficial.

Heart Rhythm 2025 Heart Rhythm Society President Kenneth A. Ellenbogen, MD

Heart Rhythm 2026 to feature late-breaking EP data, hands-on training and more

Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.

Gregg Stone, MD, FACC, FSCAI, Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai Hospital in New York, presented the results of the long-awaited STEMI Door or Unloading time trial, which takes a different approach to first using a percutaneous heart pump to unload the heart 30 minutes prior to PCI interventions to try and prevent common complications and improve outcomes.

Late-breaking PCI data challenge the 'time is muscle' paradigm

Gregg Stone, MD, spoke to Cardiovascular Business about the lessons he and his colleagues learned from the STEMI DTU trial.

Early SAVR in asymptomatic heart patients linked to long-term benefits

New 10-year data explored the impact of performing SAVR on asymptomatic patients with severe aortic stenosis.

One of the big late-breaking trials presented at the 2026 American College of Cardiology (ACC) Scientific Sessions was the CHAMPION-AF, which showed left atrial appendage occlusion (LAAO) can offer a safe, non-drug alternative to anticoagulation therapy, even in patients with atrial fibrillation who are not at high risk for bleeding. First author of the study Shephal Doshi, MD, FACC, an electrophysiologist at Cedars Sinai Smidt Heart Institute, discussed the details of the trial. #LAAO #ACC #ACC26

New data point to LAAO as a safe alternative to long-term drug therapy

At the end of the day, one electrophysiologist explained, these decisions should still be made on a case-by-case basis.

PFA associated with heightened stroke risk

PFA is still quite safe overall. However, new data out of EHRA 2026 suggest cardiologists have much to learn about minimizing risk during treatment.

Ultraprocessed foods may degrade muscle health, new MRI findings suggest

High consumption of these foods could lead to increased levels of intramuscular fat—a known marker of poor muscle health, according to new research published in Radiology.